ABOS

Acumen Pharmaceuticals, Inc.

NasdaqGSUSDEQUITY DELAYED

3.22

▲ 0.03 (1.04%)

MARKET · —

Price

Open

3.39

Prev close

3.19

Day high

3.34

Day low

3.14

Volume

715.64K

Market cap

—

P/E (TTM)

—

52W range

1.21 – 3.60

Trailing performance

Price return · vs SPY

Returnvs SPY

+18.35% +19.7%

+45.62% +41.9%

+26.91% +23.8%

+22.96% +11.9%

YTD

+49.76% +37.5%

+124.11% +104.1%

-53.46% -127.6%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

2.75

+17.08% from price

SMA 20

2.49

+26.86% from price

SMA 50

2.44

+29.28% from price

SMA 100

2.47

+30.64% from price

SMA 200

2.39

+32.47% from price

EMA 12

2.76

+16.58% from price

EMA 26

2.58

+25.13% from price

EMA 50

2.50

+29.09% from price

RSI (14)

77.8

Overbought

MACD (12,26,9)

0.19

Hist 0.10

ATR (14)

0.17

5.28% of price

Realised vol 30D

70.6%

Annualised

Bollinger upper

3.16

20, 2σ

Bollinger lower

1.82

20, 2σ

50 / 200 cross

Golden

2.44 vs 2.39

Trend bias

Above 200

+32.47%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.92

More volatile than market

Correlation to SPY

0.29

Largely independent

Realised vol 30D

70.6%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-37.4%

Peak to trough

Max drawdown 5Y

-95.2%

Peak to trough

ATR 14

0.17

5.28% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 3.22

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ABOS · links out to the publisher

Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ... GuruFocus.com · 10d ago Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary Moby · 10d ago Acumen Pharmaceuticals Q2 Earnings Call Highlights MarketBeat · 10d ago Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights GlobeNewswire · 10d ago Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 GlobeNewswire · 17d ago VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform Exec Edge · 33d ago Slate Medicines Appoints Mark W. Hahn to Board of Directors Exec Edge · 37d ago All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy Zacks · 38d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.